Early intravenous immunoglobulin as an effective drug for the treatment of COVID-19: A case series and case review

2Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Introduction: The outbreak of coronavirus disease 2019 (COVID-19) should be considered a serious threat to global public health. Due to a large number of infected and dead people, the development of approaches to control the epidemic condition, as well as effective and available drugs, is very important. Case Presentation: In this study, we presented three cases with COVID-19 admitted to the Imam Reza Hospital. A high dose of intravenous immunoglobulin (IVIG) was used for patients as potent and safe treatment. Moreover, case reports and case series focusing on the patients with COVID-19 were reviewed in the present study. During the literature search, 27 patients with COVID-19 were identified in 14 studies. Fever, sore throat, dry cough, fatigue, chills, and muscle pain were the common primary complications of the patients. Kaletra, oseltamivir, ceftriaxone, hydroxychloroquine, azithromycin, and IVIG were the most prevalent drugs for the treatment of COVID-19. Conclusions: Except for the current study, IVIG was utilized in two other studies to treat patients with COVID-19, who did not respond to other therapies.

Cite

CITATION STYLE

APA

Khodashahi, R., Sedaghat, A., & Khodashahi, M. (2020). Early intravenous immunoglobulin as an effective drug for the treatment of COVID-19: A case series and case review. Archives of Clinical Infectious Diseases, 15(5), 1–10. https://doi.org/10.5812/archcid.103732

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free